Fig. (5).

The schema of T-817MA efficacy to prevent the onset or progression of schizophrenia. T-817MA have shown the ability in vivo or animal models of schizophrenia to ①reverse the decrease in the number of parvalbumin (PV) -positive GABAergic interneurons in the mPFC and hippocampus, ②facilitate neurogenesis, such as neuron proliferation, neurite outgrowth, and synaptogenesis, through the increase of neurotrophic factors and ③elicit neuroprotective effects against H2O2-induced neurotoxicity through attenuation of reactive oxygen species (ROS) production in mitochondria.